By creating unity across all products in the portfolio, a company can position themselves as a comprehensive source for all treatment needs within a therapy area.
Our work with multiple brands – including experience with infliximab and adalimumab biosimilars – has convinced us of the value of this approach in differentiating a company’s biosimilar offerings and achieving a sustainable position in the rapidly evolving treatment landscape.
Defining the added value that the portfolio provides over individual brands
Preserving the unique identify of each biosimilar brand while leveraging the wider portfolio
Supporting patients throughout their treatment journey, including resources around co-morbidities and other aspects of holistic disease management
How can company reputation and existing brand loyalty be harnessed to make your portfolio stand out?
Which support services across the product portfolio are most valued by HCPs and patients?
How can you most effectively support HCPs and add value in their clinical practice?
Whatever your market scenario, our team is here to support you with addressing the unique challenges facing your biosimilar brand.